| # | Drug | Count |
|---|---|---|
| 0 | CABOTEGRAVIR AND RILPIVIRINE | 459 |
| 1 | RILPIVIRINE | 272 |
| 2 | CABOTEGRAVIR | 254 |
| 3 | BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE | 89 |
| 4 | DOLUTEGRAVIR SODIUM AND LAMIVUDINE | 32 |
| 5 | CABOTEGRAVIR SODIUM | 31 |
| 6 | IBALIZUMAB | 11 |
| 7 | DARUNAVIR | 10 |
| 8 | DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE | 10 |
| 9 | PEGLOTICASE | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CABOTEGRAVIR AND RILPIVIRINE | 459 | 0.0702 |
| 1 | RILPIVIRINE | 272 | 0.0381 |
| 2 | CABOTEGRAVIR | 254 | 0.0310 |
| 3 | IBALIZUMAB | 11 | 0.0204 |
| 4 | CABOTEGRAVIR SODIUM | 31 | 0.0193 |
| 5 | FOSTEMSAVIR TROMETHAMINE | 3 | 0.0123 |
| 6 | DOLUTEGRAVIR SODIUM AND LAMIVUDINE | 32 | 0.0089 |
| 7 | DORAVIRINE | 4 | 0.0051 |
| 8 | TIRBANIBULIN | 1 | 0.0040 |
| 9 | DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE | 10 | 0.0036 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD4-directed Blocking Antibody [EPC] | 11 | 0.0204 |
| 1 | Uric Acid-specific Enzyme [EPC] | 10 | 0.0026 |
| 2 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 3 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 145 | 0.0013 |
| 4 | Insulin-like Growth Factor-1 Receptor Inhibitor [EPC] | 7 | 0.0012 |
| 5 | Pyrethroid [EPC] | 2 | 0.0011 |
| 6 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 38 | 0.0008 |
| 7 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 8 | Protease Inhibitor [EPC] | 20 | 0.0004 |
| 9 | Antiparasitic [EPC] | 2 | 0.0004 |